Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

N/AActive Not RecruitingNCT00457587

University of Wuerzburg150 enrolled

Overview

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Adrenocortical Carcinoma Cushing's Syndrome

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * patients with histological proven adrenocortical carcinoma * healthy persons as control group * Life expectancy \> 6 months Exclusion Criteria: * autoimmune diseases * severe clinical condition

Locations (1)

Dept. of Medicine I, University of Wuerzburg

Würzburg, Germany

Outcomes

Primary Outcomes

To find reasonable antigens for a vaccination therapy in ACC

Time frame: day of blood sampling

To investigate the role of tumor-induced suppression in ACC

Time frame: NA, in vitro study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.